Investing.com - Bristol-Myers Squibb (NYSE: BMY) reported second quarter EPS of $2.07, $0.43 better than the analyst estimate of $1.64. Revenue for the quarter came in at $12.2B versus the consensus estimate of $11.52B.
Guidance
Bristol-Myers Squibb sees Q3 2024 EPS of $0.60-$0.90 versus the analyst consensus of $0.51.
Bristol-Myers Squibb's stock price closed at $45.27. It is up 0.94% in the last 3 months and down -25.46% in the last 12 months.
Bristol-Myers Squibb saw 1 positive EPS revisions and 13 negative EPS revisions in the last 90 days. See Bristol-Myers Squibb's stock price’s past reactions to earnings here.
According to InvestingPro, Bristol-Myers Squibb's Financial Health score is "good performance".
Check out Bristol-Myers Squibb's recent earnings performance, and Bristol-Myers Squibb's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar